TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03067207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MARS-A
Description: The intervention will consist of the 8-week mindfulness meditation program designed for adolescents with chronic health conditions.MARS-A is based on two established mindfulness-based interventions for adults: MBSR and MBCT. The content of the program will be the same for in-person and e-health groups: all participants will receive eight 90-minute weekly evening sessions led by two trained and experienced mindfulness providers. Sessions will include short meditation practices, breathing exercises, guided discussion, mindful movements and inquiry, adapted to the context of chronic illness. Every session will start with a brief review of home practice and will close with a discussion of the home practice for the following week.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MARS-A
Description: The intervention will consist of the 8-week mindfulness meditation program designed for adolescents with chronic health conditions.MARS-A is based on two established mindfulness-based interventions for adults: MBSR and MBCT. The content of the program will be the same for in-person and e-health groups: all participants will receive eight 90-minute weekly evening sessions led by two trained and experienced mindfulness providers. Sessions will include short meditation practices, breathing exercises, guided discussion, mindful movements and inquiry, adapted to the context of chronic illness. Every session will start with a brief review of home practice and will close with a discussion of the home practice for the following week.
Study: NCT04007640

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI with additional sequences
Description: MRI with 15 min additional sequences to validate and assess pancreatic MRI sequences

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI
Description: MRI with 15 min additional sequences to validate and assess pancreatic MRI sequences

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Left pancreatectomy or pancreaticoduodenectomy
Description: Histological analysis :

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Left pancreatectomy or pancreaticoduodenectomy
Description: Histological analysis :

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Left pancreatectomy or pancreaticoduodenectomy
Description: Histological analysis :

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI with additional sequences
Description: MRI with 15 min additional sequences to assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI with additional sequences
Description: MRI with 15 min additional sequences to assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI with additional sequences
Description: MRI with 15 min additional sequences to assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients
Study: NCT00396279

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Administered by subcutaneous injection

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium/Vitamin D
Study: NCT00906594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: latanoprost
Study: NCT05179681

Intervention type: OTHER
Intervention: Nasal High -Flow Oxygen Therapy
Description: patients receiving transnasal humidified rapid-insufflation ventilatory exchange
Study: NCT01565902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312
Description: Treatment with a single oral dose of 0.25 mg BAF312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312
Description: Treatment with a single oral dose of 0.25 mg BAF312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312
Description: Treatment with a single oral dose of 0.25 mg BAF312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312
Description: Treatment with a single oral dose of 0.25 mg BAF312
Study: NCT01219322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: single use of sodium bicarbonate and sterile water for injection 1:1 concentration 50 cc

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: intravenous normal saline volume equivalent to sodium bicarbonate
Study: NCT01591122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo and prednisone
Description: Placebo: Form=tablet, route=oral. Four tablets daily on an empty stomach. Prednisone: Type=exact number, unit=mg, number=5, form=tablet, route=oral, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate and prednisone
Description: Abiraterone acetate: Type=exact number, unit=mg, number=250, form=tablet, route=oral. Four tablets daily on an empty stomach Prednisone: Type=exact number, unit=mg, number=5, form=tablet, route=oral, twice daily
Study: NCT02336165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is administered as an IV infusion over 60 ± 5 minutes Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is administered as an IV infusion over 60 ± 5 minutes Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is administered as an IV infusion over 60 ± 5 minutes Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is administered as an IV infusion over 60 ± 5 minutes Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is administered as an IV infusion over 60 ± 5 minutes Q2W.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard radiotherapy
Description: Focal radiotherapy is administered at 2 Gy given daily 5 days per week for a total of 60 Gy over 30 fractions per local institutional guidelines or local prescribing information. On days when radiotherapy and durvalumab overlap, radiotherapy is administered first followed by durvalumab.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is administered as an IV infusion (per local prescribing information) Q2W. When durvalumab and bevacizumab are administered together (i.e., Cohorts B2, B3, and C), durvalumab is administered first followed by a 1-hour observation period, after which, bevacizumab is infused.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is administered as an IV infusion (per local prescribing information) Q2W. When durvalumab and bevacizumab are administered together (i.e., Cohorts B2, B3, and C), durvalumab is administered first followed by a 1-hour observation period, after which, bevacizumab is infused.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is administered as an IV infusion (per local prescribing information) Q2W. When durvalumab and bevacizumab are administered together (i.e., Cohorts B2, B3, and C), durvalumab is administered first followed by a 1-hour observation period, after which, bevacizumab is infused.
Study: NCT01789294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: A standard 50 mg/kg/die daily dose of oral mesalamine was prescribed by Pediatric Gastroenterologists, which informed parents of potential side effects. Whether the drug was not well tolerated, patients were drop out. Treatment was discontinued at time 1 to look for symptom recurrence.
Study: NCT01909791

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prompt Laser
Description: Focal/grid laser performed at baseline and as needed during follow-up

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prompt aflibercept
Description: Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deferred laser
Description: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deferred laser
Description: Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferred aflibercept
Description: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferred aflibercept
Description: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria
Study: NCT02350751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8852

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01558128

Intervention type: DRUG
Group type: OTHER
Intervention: Amiodarone
Description: Bolus given 150mg IV, then IV drip 1mg per hour infused for 6 hours, 0.5mg per hour infused for 18 hours.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cardioversion
Description: Cardioversion done if atrial fibrillation continues following 24 hour infusion of amiodarone. Cardioversion done following hospital protocol.
Study: NCT01075633

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immunochemical fecal occult blood test And colonoscopy if test is positive
Description: Annual (3 rounds), without diet restriction, 1 stool sample. Positive cut-off level: 50 ng/ml.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy with sedation
Description: Colonoscopy with sedation
Study: NCT00782470

Intervention type: BEHAVIORAL
Intervention: Recombinant Factor VIII (Kogenate, BAY 14-2222)
Description: Subjects electing to stay on the prophylactic treatment (prospective)
Study: NCT01789294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIET
Description: Dietetic avoidance of cow's milk and egg, plus foods eventually detected by skin tests, was prescribed by Pediatric Allergologists. To ensure the correct adherence to diet with no nutritional impairment, a scheme of admitted foods and an appropriate calcium supplement dose were given to patients.
Study: NCT02099747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hATG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hATG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CsA
Study: NCT00782470

Intervention type: BEHAVIORAL
Intervention: Recombinant Factor VIII (Kogenate, BAY 14-2222)
Description: Subjects electing to switch to on-demand treatment (prospective)

Intervention type: BEHAVIORAL
Intervention: Recombinant Factor VIII (Kogenate, BAY 14-2222)
Description: Subjects remaining on-demand treatment (retrospective)
Study: NCT02099747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Study: NCT04527575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)
Description: EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide). The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations spaced 21-28 days apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)
Description: EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide). The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations spaced 21-28 days apart.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%)
Description: The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (43 volunteers)
Study: NCT01476085

Intervention type: RADIATION
Group type: NO_INTERVENTION
Intervention: ML10
Description: \[18F\]ML10 radioligand apoptosis biomarker
Study: NCT02236494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Negotiated Interview
Description: As per arm

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Information
Description: As per arm (this is the active comparator)
Study: NCT02991404

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Peripheral Nerve Block Injection
Description: After successful placement of the adductor canal catheter placed in standard fashion , the patient will receive a one-time 20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine followed by a continuous infusion of 0.125% bupivacaine set at 10ml/hour.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Single Shot Adductor Canal Block
Description: A total of 20 ml of solution containing a combination of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, 150 micrograms of buprenorphine, 2 mg of dexamethasone, and 1:400,000 epinephrine will be administered underneath the Sartorius muscle. A sham catheter will then be placed subcutaneously into the Sartorius muscle, secured in typical fashion, and connected to a pump containing saline to provide similar shape and weight with an opaque bag covering the pump. The pump will be run at the lowest possible ml/hour rate, which is currently 0.1 ml/hour with the current pump used in our hospital.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Initial Bolus
Description: 20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Initial Bolus
Description: 20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous infusion
Description: Continuous infusion of 0.125% bupivacaine
Study: NCT01541891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-148 Ophthalmic Solution
Description: PRO-148 Ophthalmic Solution applied four times per day (c/6 hours) during 60 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: SYSTANE ® Ophthalmic Solution
Description: Sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, boric acid, calcium chloride, magnesium chloride, potassium chloride, sodium chloride, zinc chloride and polyquad (polidronium chloride) 0,001%. four times per day (c/6 hours) during 60 days.
Study: NCT00893386

Intervention type: PROCEDURE
Intervention: LV Lead Extraction
Description: Removal of a LV lead using any tools \& techniques.

Intervention type: PROCEDURE
Intervention: LV Lead Extraction
Description: Removal of a LV lead using any tools \& techniques.

Intervention type: PROCEDURE
Intervention: LV Lead Extraction
Description: Removal of a LV lead using any tools \& techniques.
Study: NCT02440308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-Bombesin
Description: 68Ga-DOTA-Bombesin is a gallium-68-labeled gastrin-releasing peptide receptor (GRPr) antagonist. DOTA is \[4,7,10-Tris-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl\]-acetyl.~68Ga-DOTA-Bombesin is administered intravenously (IV)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) scan
Study: NCT04597463

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial injury
Description: Endometrial injury was performed hysteroscopically after freeze all cycles and during the cycle before the frozen embryo transfer
Study: NCT04544787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel OPV2 candidate 1
Description: Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 1 (S2/cre5/S15domV/rec1/hifi3).~Modifications included the following:~* Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~* Two modifications in the polymerase 3D to further improve stability of the attenuation and reduce frequency of recombination events~* Relocation of a key replication element from the 2C coding region to the 5'-untranslated region, to inhibit recombination.
Study: NCT03700099

Intervention type: DRUG
Group type: OTHER
Intervention: Enzalutamide
Description: Upon disease progression after treatment with docetaxel, patients will receive Enzalutamide 160 mg P.O. daily until disease progression or limiting toxicity.
Study: NCT01511757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Fluconazole Tablets, 200 mg
Study: NCT02284087

Intervention type: DEVICE
Intervention: PAS

Intervention type: DEVICE
Intervention: PAS
Study: NCT00433147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afegostat tartrate
Study: NCT00715143

Intervention type: DEVICE
Group type: OTHER
Intervention: Novation Ceramic
Description: This treatment is the study device (which will be compared to a similar historic control device)
Study: NCT00433147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afegostat tartrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afegostat tartrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afegostat tartrate
Study: NCT01090713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisdexamfetamine
Description: oral; 20-70mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: 20-70mg; oral
Study: NCT04667091

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Treatment will be given in 3 sessions per week for 6 weeks with home exercise program and participants will be provided with exercises sheets to remember the exercises.~The selected outcome measure will be taken on baseline (initial visit) and 6th week (post intervention)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Treatment will be given in 3 sessions per week for 6 weeks with home exercise program and participants will be provided with exercises sheets to remember the exercises.~The selected outcome measure will be taken on baseline (initial visit) and 6th week (post intervention)
Study: NCT00910663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 250 mg Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CellCept®
Description: 250 mg Capsule
Study: NCT00812162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Restriction
Description: Energy restricted diet of 750 kcal less than subjects requirement with a high protein diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Restriction
Description: Energy restricted diet of 750 kcal less than subjects requirement with a lower protein diet.
Study: NCT00880568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1496
Description: MK-1496 (20 to 120 mg), orally, administered on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1496
Description: MK-1496 (20 to 120 mg), orally, administered on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1496
Description: MK-1496 (20 to 120 mg), orally, administered on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1496
Description: MK-1496 (20 to 120 mg), orally, administered on Day 1 of each 21-day cycle
Study: NCT02117128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Study: NCT00880568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1496
Description: MK-1496 (20 to 120 mg), orally, administered on Days 1 and 3 each week for 3 weeks (Days 1, 3, 8, 10, 15 and 17) of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1496
Description: MK-1496 (20 to 120 mg), orally, administered on Days 1 and 3 each week for 3 weeks (Days 1, 3, 8, 10, 15 and 17) of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1496
Description: MK-1496 (20 to 120 mg), orally, administered on Days 1 and 3 each week for 3 weeks (Days 1, 3, 8, 10, 15 and 17) of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1496
Description: MK-1496 (20 to 120 mg), orally, administered on Days 1 and 3 each week for 3 weeks (Days 1, 3, 8, 10, 15 and 17) of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1496
Description: MK-1496 (20 to 120 mg), orally, administered on Days 1 and 3 each week for 3 weeks (Days 1, 3, 8, 10, 15 and 17) of each 28-day cycle
Study: NCT02527278

Intervention type: PROCEDURE
Intervention: Laparoscopic tubal ligation
Description: Female permanent birth control method performed via a surgical procedure

Intervention type: PROCEDURE
Intervention: Laparoscopic tubal ligation
Description: Female permanent birth control method performed via a surgical procedure

Intervention type: PROCEDURE
Intervention: Hysteroscopic sterilization
Description: Female permanent birth control method performed via placement of a device

Intervention type: PROCEDURE
Intervention: Hysteroscopic sterilization
Description: Female permanent birth control method performed via placement of a device
Study: NCT02259270

Intervention type: OTHER
Intervention: Record review
Description: Record review. No intervention with patient or physician. No effect on outcome.

Intervention type: OTHER
Intervention: AST-history
Description: Checking history (period and number) of ambulatory dispensed AST from 1 year before till 1 year after hospitalisation. No intervention with patient or physician. No effect on outcome.
Study: NCT01175616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Oral Creatine 5 grams daily.
Study: NCT03728296

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: islet body
Description: Transplanting islet bodies under the diaphragm
Study: NCT00726739

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: IL-2 Alone - administer 10 x 10\^6 International Units subcutaneously (SQ) will be given on day 1 and day 2 every 4 weeks until disease progression or for a maximum of 12 treatment cycles.
Study: NCT02117128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid